Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

Boxplot showing differences in vertebral cross-sectional growth between girls with increased (<i>n</i> = 14) and decreased vertebral body wedging (<i>n</i> = 13); <i>p</i> = 0.001. by Ervin Poorghasamians (3801475)

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

The waveforms of motor axons excitability parameters were presented as mean with SE for the paretic (black, n = 22), non-paretic (white, n = 22) limbs, and the sex and age-matched... by Hung-Ju Chen (13842312)

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Chronic exposure of human PAC to nicotine decreases carrier-mediated [³H] thiamin uptake. by Padmanabhan Srinivasan (481324)

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects: